From: A mathematical model with time-varying delays in the combined treatment of chronic myeloid leukemia
Param | Physical interpretation | Estimated value (units) | Reference |
---|---|---|---|
τ | delay for development of CTL cells | 7 [days] | [9] |
θ | maximal period to react to imatinib | 20 [days] | [6] |
${\mu}_{x}$ | death rate of cancer cells | 0.2 [0, 0.8] [days^{−1}] | [23] |
${\mu}_{y}$ | death rate of effector T cells | 0.06 [0, 0.5] [days^{−1}] | [24] |
${\eta}_{1}$ | saturation effect of CML cells in the lymph nodes | 100 [cells][ml^{−1}] | [9] |
${\eta}_{2}$ | saturation effect of immune cell recruitment by cancer cells | 2 × 10^{7} [cells][ml^{−1}] | [24] |
${\beta}_{1}$ | growth rate of CML cancer cells in the form of the Gompertz law | 0.03 [0; 0.5] [days^{−1}] | [9] |
${\beta}_{2}$ | change in the effector T cell (y(t)) population due to encounters with CML antigen | 0.41 × 0.001 [days^{−1}] | [25], [26] |
${\gamma}_{1}$ | loss of CML cancer cells due to encounters with the effector T cells | $0.005\phantom{\rule{0.1em}{0ex}}{\text{[days}}^{-1}{[\frac{\text{cells}}{\text{ml}}]}^{-1}\text{]}$ | [9] |
${\gamma}_{2}$ | loss of CTL cells due to these encounters between CTL and CML cancer cells | $0.005\phantom{\rule{0.1em}{0ex}}{\text{[days}}^{-1}{[\frac{\text{cells}}{\text{ml}}]}^{-1}\text{]}$ | [26] |
${\gamma}_{3}$ | factor using imatinib treatment | 0.00014 [mg]^{−1} | Estimated |
${\gamma}_{4}$ | factor using IFN-a treatment | 0.005 [mg]^{−1} | Estimated |
ω | once-daily dose of imatinib | 400 - 800 [mg/day] | [1] |
$i{n}_{\alpha}$ | IFN-a dose | 13 [mg/days] (90 [mg] weekly) | [27] |
K | constant, the maximum possible concentration of CML | [1.5 × 10^{5};4 × 10^{5}] [cells/ml] | [9] |